The course is designed to assist nephrologists and nephropathologists in diagnosing and managing the most common forms of medical renal disease, including diseases that target the glomerulus, tubules, interstitium and blood vessels. The activity will span three weeks and will include a combination of pre-recorded lectures and live sessions covering the following content areas: Week 1 (June 26, 2020): Nephrotic syndrome Week 2 (July 3, 2020): Nephritic syndromes Week 3 (July 10): Tubulointerstitial, Vascular, Dysproteinemia, & Transplant Each week will consist of approximately 8 hours of asynchronous content culminating in a 2 hour and 15-minute live session. The live sessions will be held on July 2, 9, and 16 and will consist of: • 45 minutes of Q&A/panel discussion with faculty focusing on the lectures for the week. • 45 minutes of 2 CPC cases, with pathologist and clinicians from Columbia University Irving Medical Center • 45 minutes of “show & tell” renal pathology lab – 7-10 cases per day Upon completion of this activity, participants will be better able to understand: • the pathophysiology and clinical aspects of the major parenchymal diseases of the kidney, with emphasis on clinical-pathologic correlations and the role of renal biopsy. • pathology, pathophysiology, pathogenesis, clinical presentation, prognosis, and optimal therapy for many different medical renal diseases, including but not limited to minimal change disease, FSGS, membranous nephropathy, amyloidosis, membranoproliferative glomerulonephritis, IgA nephropathy, hereditary nephritis, acute post-infectious glomerulonephritis, amyloidosis, light chain deposition disease, myeloma cast nephropathy, cryoglobulinemic glomerulonephritis, lupus nephritis, and diabetic nephropathy. This activity has been approved for AMA PRA Category 1 Credit™ CLICK HERE to view the full agenda

The speakers are Anouchka Laurent (Ferrando Lab) and Wei Gu.

This webinar will share updates on glioblastoma therapies and research. The panelists will present new therapeutic options across multiple modalities, including surgical approaches such as convection-enhanced delivery (CED), immunotherapy, and frameless stereotactic radiosurgery/hypofractionated radiotherapy approaches. Target Audience: Medical oncologists, radiation oncologists, neurologists, primary care physicians and other health professionals, in addition to patients, family members, and patient advocates. Upon conclusion of this activity, participants will be better able to: • Describe appropriate selection for frameless stereotactic radiosurgery and hypofractionated radiotherapy for newly diagnosed and recurrent glioblastomas • Discuss the benefits of convection enhanced delivery to optimize chemotherapy for brain tumors • Explain how the use of fluorescent compounds can lead to safe, maximal resection of invasive brain tumors AGENDA 5:30-5:50 | Tony Wang, MD: “Advances on Radiosurgical/Radiotherapy Approaches to Brain Tumors” 5:50-6:10 | Jeffrey Bruce, MD, FACS: “Novel Surgical Approaches to Glioblastoma” 6:10-6:30 | Andrew Lassman, MD: “Updates on Medical Therapies for Glioblastoma” 6:30-7:00 | Q&A This activity has been approved for AMA PRA Category 1 Credit™

The speaker is Anil Rustgi, MD. Hosted by Riccardo Dalla-Favera.